In a compelling and highly anticipated live interview streamed on Instagram, Facebook, and Zoom, integrative gastroenterologist Dr. Elena Ivanina, MD, MPH, hosted a global conversation with Nir Salomon, ChB, co-founder of Evinature and Director of the Integrative Gastroenterology Unit at Sheba Medical Center in Israel. The session offered a deep dive into the CurQD® Protocol, Evinature’s flagship nutraceutical protocol for IBD, and the growing role of evidence-based natural therapies in modern gut health treatment.
A Meeting of Minds: Integrative Medicine Meets Clinical Rigor
Dr. Ivanina, founder of Gut Love and a triple board-certified expert in gastroenterology, functional medicine, and preventive care, opened the conversation by introducing Salomon’s impressive research pedigree. Salomon co-developed the CurQD® Protocol alongside Prof. Shomron Ben-Horin after a decade of rigorous clinical research at Sheba Medical Center—one of the top hospitals in the world.
“What started as a clinical experiment backed by patient donations evolved into a multinational, award-winning treatment program,” Salomon explained. “The first trial of gut-directed curcumin and Qing Dai for ulcerative colitis was funded entirely by patients. Their support is what launched this research, even before Evinature existed.”
From Clinic to Clinical Trials
The pair discussed how Salomon’s early work in Traditional Chinese Medicine and integrative gastroenterology laid the groundwork for Evinature’s clinical success. With the support of Sheba’s R&D team, he and Prof. Ben-Horin spearheaded international randomized controlled trials, earning recognition from the Crohn’s & Colitis Foundation and leading medical journals.
Dr. Ivanina praised this rigorous approach to natural medicine: “You don’t often see supplement companies publishing in peer-reviewed journals or earning distinctions at medical conferences. Evinature is doing it differently.”
CurQD®: A Real-World Solution for Real Patients
The live discussion addressed the science and strategy behind the CurQD® Protocol—a six-week, gut-directed regimen that combines herbal anti-inflammatories with microbiome support. Salomon emphasized that CurQD® is used as an adjunct therapy, often added to standard medications like mesalamine to enhance their effectiveness and prevent dose escalation.
“Most patients don’t need to abandon conventional medicine. They just need something to help it work better,” Salomon said. “That’s where CurQD® comes in.”
Evidence Across IBD Types—Including Crohn’s
Salomon revealed that new research on CurQD® for Crohn’s disease has just been accepted into a leading journal, expanding the product’s evidence base beyond ulcerative colitis. “We’re seeing the same efficacy patterns in small bowel Crohn’s as we did in UC,” he noted. “It’s a big moment for patients in need of safe, non-immunosuppressive options.”
Personalized, Patient-Led Care
Dr. Ivanina also highlighted Evinature’s unique model of patient care: an online assessment tool that recommends one of six personalized protocols, followed by proactive clinical support.
“It’s a real partnership between the patient, Evinature’s clinical team, and the treating physician,” she said. “And that kind of engagement is what makes long-term remission possible.”
What’s Next: Pregnancy, Pediatrics, and Protocol Adaptation
Audience questions touched on safety during pregnancy and breastfeeding, pediatric use, and flare-up management. Salomon confirmed that a low-dose version of CurQD®, known as Cura, is already being used in these sensitive populations, with ongoing research to support broader applications.
A Shared Mission
“We both believe that gut health deserves a whole-person, evidence-driven approach,” Dr. Ivanina concluded. “And that patients deserve more than band-aid solutions.”
Check out the full interview below:
Evinature
